http://www.curetoday.com/cure-tv/d-ross-camidge-discusses-the-development-of-a-new-lung-cancer-drug
D. Ross Camidge on the Development of a New Lung Cancer Drug

D. Ross Camidge

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.
Print | cure Printing...